Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
Status:
Recruiting
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This study explores whether a commonly used medication called Pantoprazole can help prevent
delayed nausea and vomiting from chemotherapy for early breast cancer.
Delayed nausea, and occasionally vomiting, can occur after breast cancer chemotherapy,
affecting quality of life. A potential cause of these delayed side effects is that the
chemotherapy may cause stomach irritation. Pantoprazole is commonly used to treat stomach
irritation by reducing stomach acid, which may in turn improve nausea and/or vomiting.
Patients undergoing breast cancer chemotherapy before or after primary surgery will be
invited to participate in the study. They will be asked how much nausea or vomiting they have
with and without Pantoprazole from Day 2 until 5 after they receive chemotherapy. All
participants will still receive all of the usual anti-sickness medications, which are very
effective in preventing sickness in the first 24 hours after treatment, but not for delayed
symptoms.
Information from the study may lead to a change in practice with patients using Pantoprazole
to reduce the risks of delayed nausea and vomiting.